We use cookies, including third-party cookies from Google to serve personalized ads through AdSense, to operate this site and understand how it is used. By continuing to browse, you accept this use. See our Privacy Policy and Terms of Use for details, including how to opt out of personalized advertising.
Accept
Health Works CollectiveHealth Works CollectiveHealth Works Collective
  • Health
    • Mental Health
  • Policy and Law
    • Global Healthcare
    • Medical Ethics
  • Medical Innovations
  • News
  • Wellness
  • Tech
Search
© 2023 HealthWorks Collective. All Rights Reserved.
Reading: Type 1 Diabetes Addressed By “Silencing Immune Attacks” (Children’s Hospital, Boston)
Share
Notification Show More
Font ResizerAa
Health Works CollectiveHealth Works Collective
Font ResizerAa
Search
Follow US
  • About
  • Contact
  • Privacy
© 2023 HealthWorks Collective. All Rights Reserved.
Health Works Collective > Technology > Medical Innovations > Type 1 Diabetes Addressed By “Silencing Immune Attacks” (Children’s Hospital, Boston)
Medical Innovations

Type 1 Diabetes Addressed By “Silencing Immune Attacks” (Children’s Hospital, Boston)

PatrickDriscoll
PatrickDriscoll
Share
2 Min Read
Image
SHARE

Image

Image

Researchers at Children’s Hospital in Boston have reported in the online edition of Diabetes that they have identified the specific molecular pathway involved in triggering the autoimmune response at the root of type 1 diabetes. The research team studied “hundreds” of pathways in animals with diabetes and ultimately identified one, known as ATP/P2X7R, which triggers the immune system’s T-cell attacks on the pancreas that subsequently prevent the pancreas from producing insulin.

While this research is akin in some ways to many disease research discoveries that are dramatic but that have not led to cures or significant advances in treatment, the discovery of the root pathway in type 1 diabetes is significant for the fact that it opens up the possibility of, on the one hand, interrupting this pathway in order to the autoimmune destruction of patients’ insulin-producing islet cells and, on the other hand, interrupting this pathway to similarly prevent destruction of islet transplant cells. It may well be years before this leads to treatment options, which may include “drug therapies to transplants that require less immunosuppression” for patients with existing type 1 diabetes and options to even prevent type 1 from developing in children.

More Read

How That New Drug Goes From Idea to Market
Hospital Staff Cuts Dose for Pediatric Exams in Half with a Testing/Evaluation Process
Why You Should Care About Your Personal Health Record and Access to Your Data
SRI International – Innovation Starts Here
The PCMH and Home Care Data: An Interview with Melissa McCormack
     

TAGGED:diabetes
Share This Article
Facebook Copy Link Print
Share
By PatrickDriscoll
Follow:
I serve the interests of medical technology company decision-makers, venture-capitalists, and others with interests in medtech producing worldwide analyses of medical technology markets for my audience of mostly medical technology companies (but also rapidly growing audience of biotech, VC, and other healthcare decision-makers). I have a small staff and go to my industry insiders (or find new ones as needed) to produce detailed, reality-grounded analyses of current and potential markets and opportunities. I am principally interested in those core clinical applications served by medical devices, which are expanding to include biomaterials, drug-device hybrids and other non-device technologies either competing head-on with devices or being integrated with devices in product development. The effort and pain of making every analysis global in scope is rewarded by my audience's loyalty, since in the vast majority of cases they too have global scope in their businesses.Specialties: Business analysis through syndicated reports, and select custom engagements, on medical technology applications and markets in general/abdominal/thoracic surgery, interventional cardiology, cardiothoracic surgery, patient monitoring/management, wound management, cell therapy, tissue engineering, gene therapy, nanotechnology, and others.

Stay Connected

1.5KFollowersLike
4.5KFollowersFollow
2.8KFollowersPin
136KSubscribersSubscribe

Latest News

The Case for Proactive Nutrient Support and Where IV Therapy Fits In -- AI-generated illustration
The Case for Proactive Nutrient Support and Where IV Therapy Fits In
Health Therapies
October 5, 2026
Biofeedback Technology in Addiction Treatment: What the Evidence Shows So Far -- AI-generated illustration
Biofeedback Technology in Addiction Treatment: What the Evidence Shows So Far
Addiction Addiction Recovery
September 28, 2026
Charity Care Is Written Into Hospital Policy. It Rarely Makes It Onto the Bill. -- AI-generated illustration
Charity Care Is Written Into Hospital Policy. It Rarely Makes It Onto the Bill.
Business Hospital Administration
September 25, 2026
A Global Perspective on Medicine: Lessons Learned Across Borders -- AI-generated illustration
A Global Perspective on Medicine: Lessons Learned Across Borders
Medicines
September 23, 2026

You Might also Like

Diabetes, Insulin, Social Media: Results of Tweetchat #doctors20

February 21, 2013
Medical DevicesMedical InnovationsTechnology

Healthcare Tech Advances That All Clinics Should Use

August 12, 2017
Standing room only at the APTA 2013 Conference
Health ReformMedical InnovationsPublic HealthWellness

Innovative Care Models for Prevention, Health Promotion, Fitness and Disease Management

July 2, 2013

RNAi Firm Raises Funds to Develop Drugs That Turn Off Disease-Causing Genes

October 22, 2013
Subscribe
Subscribe to our newsletter to get our newest articles instantly!
Follow US
© 2008-2026 HealthWorks Collective. All Rights Reserved.
  • About
  • Contact
  • Privacy
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?